Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-465-5 | CAS number: 141-17-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Bacterial Mutagenicity (OECD 471, GLP), Ames: negative with and without metabolic activation
Cytogenicity/micronucleus test in peripheral human lymphocytes (OECD 487, GLP): negative with and without metabolic activation
Gene mutation in mammalian cells (OECD 490, GLP): negative with and without metabolic activation
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 22 July to 17 August 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP - Guideline study
- Qualifier:
- according to guideline
- Guideline:
- JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.5100 (Escherichia coli WP2 and WP2 UVRA Reverse Mutation Test)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.5265 (The Salmonella typhimurium Bacterial Reverse Mutation Test)
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- his operon (Salmonella typhimurium strains); trp operon (E.coli strains)
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- E. coli WP2 uvr A pKM 101
- Metabolic activation:
- with and without
- Metabolic activation system:
- cofactor supplemented post-mitochondrial fraction (S9 mix), prepared from the livers of rats treated with Aroclor 1254
- Test concentrations with justification for top dose:
- Preliminary Toxicity Test
0.15, 0.5, 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate
Experiment 1 and 2
50, 150, 500, 1500 and 5000 µg/plate - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: dimethyl sulfoxide
The test material was immiscible in sterile distilled water at 50 mg/mL but was fully miscible in dimethyl sulphoxide at the same concentration. - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- 9-aminoacridine
- N-ethyl-N-nitro-N-nitrosoguanidine
- benzo(a)pyrene
- other: 2-aminoanthtracene (2AA)
- Remarks:
- +S9: 2AA (all strains); -S9: N-ethyl-N-nitro-N-nitrosoguanidine (ENNG), benzo(a)pyrene (BP), 9-aminoacridine (9AA), 4-nitroquinoline-N-oxide (4NQO)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION:
Standard plate incorporation method (experiment 1) and preincubation method (experiment 2)
DURATION
- Preincubation period: 20 min (only exp 2)
- Exposure duration: 48 h at 37 °C (exp 1 and 2)
NUMBER OF REPLICATIONS:
3 replicates/strain
DETERMINATION OF CYTOTOXICITY
Any toxic effects of the test substance would be detected by a substantial reduction in revertant colony counts or by the absence of a complete bacterial lawn. - Evaluation criteria:
- Acceptance Criteria:
The following criteria must be met for acceptance:
- All tester strain cultures must exhibit a characteristic number of spontaneous revertants per plate in vehicle and untreated controls.
- The appropriate characteristics of each tester strain must be confirmed, eg rfa cell-wall mutation and pKM101 plasmid R-factor.
- All tester strain cultures should be in the range of 0.9 to 9.9 x 10^9 bacteria per mL.
- Each mean positive control value should be at least 2x the respective vehicle control value for each strain, thus demonstrating both the intrinsic sensitivity of the tester strains and the integrity of the S9-mix
- The test should include a minimum of four non-toxic dose levels.
Evaluation Criteria:
There are several criteria for determining a positive result. Any, one, or all of the following may be used to determine the overall result of the study:
- A dose-related increase in mutant frequency over the dose range tested.
- A reproducible increase at one or more concentrations.
- The biological relevance against in-house historical control ranges.
- Statistical analysis of data as determined by the UKEMS (Mahon et al., 1989).
- Fold increase greater than two times the concurrent solvent control for any tester strain (especially if accompanied by an out-of-historical range response).
A test material will be considered non-mutagenic (negative) in the test system if the above criteria are not met. - Statistics:
- Mean values with standard deviations were calculated.
- Species / strain:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- E. coli WP2 uvr A pKM 101
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING STUDIES
In order to select appropriate dose levels for use in the main test, a preliminary test were conducted in the presence or absence of metabolic activation. Ten dose levels and controls were tested up to and including 5000 µg/plate at approximately half-log intervals. The assay was conducted by mixing 0.1 mL the bacterial culture (TA 100 or WP2uvrA-), and 0.1 mL of the vehicle or test chemical mixture, 0.5 mL of S9-mix or phosphate buffer and 2.0 mL of molten agar supplemented with trace histidine or tryptophan and overlaying onto sterile plates of Vogel-Bonner Minimal agar (30 mL/plate). After approximately 48 hours incubation at 37 °C, the plates were assessed for numbers of revertant colonies using a Domino colony counter and examined for effects on the growth of the bacterial background lawn. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
- Conclusions:
- Interpretation of results (migrated information):
negative - Endpoint:
- in vitro cytogenicity / micronucleus study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 08 May - 20 July 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 487 (In vitro Mammalian Cell Micronucleus Test)
- Version / remarks:
- adopted 29 July 2016
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian cell micronucleus test
- Species / strain / cell type:
- lymphocytes: human peripheral
- Details on mammalian cell type (if applicable):
- CELLS USED
- Type and source of cells: blood was collected from healthy adult, non-smoking volunteers
- Suitability of cells: peripheral human lymphocytes are recommended in the international OECD guideline 487
- Normal cell cycle time (negative control): average generation times were determined to be 14,8 h, 14.4 h, 13.9 h and 14.2 h for the respective donors (December 2017)
For lymphocytes:
- Age and number of blood donors: 23, 26 or 32 years, 4
- Whether whole blood or separated lymphocytes were used: whole blood
- Whether blood from different donors were pooled or not: not pooled
- Mitogen used for lymphocytes: 0.1 mL (9 mg/mL) phytohaemagglutinin
MEDIA USED
- Type and composition of media, CO2 concentration, humidity level, temperature: RPMI 1640 medium (Life Technologies), supplemented with 20% (v/v) heat-inactivated (56°C; 30 min) fetal calf serum (Life Technologies), L-glutamine,(2 mM) (Life Technologies), penicillin/streptomycin (50 U/mL and 50 μg/mL respectively) (Life Technologies) and 30 U/mL heparin (Sigma, Zwijndrecht, The Netherlands); 5.0 ± 0.5% CO2, 80 - 100% (humidity), 37.0 ± 1.0°C - Cytokinesis block (if used):
- Cytochalasine B (Sigma; 5 μg/mL)
- Metabolic activation:
- with and without
- Metabolic activation system:
- Type and composition of metabolic activation system:
- source of S9 : rat S9 homogenate (Trinova Biochem GmbH, Giessen, Germany) was prepared from male Sprague Dawley rats that have been dosed orally with a suspension of phenobarbital (80 mg/kg body weight) and ß-naphthoflavone (100 mg/kg).
- method of preparation of S9 mix: S9-mix was prepared immediately before use and kept refrigerated. S9-mix components contained per mL physiological saline: 1.63 mg MgCl2.6H2O (Merck); 2.46 mg KCl (Merck); 1.7 mg glucose-6-phosphate (Roche, Mannheim, Germany); 3.4 mg NADP (Randox Laboratories Ltd., Crumlin, United Kingdom); 4 μmol HEPES (Life Technologies). The above solution was filter (0.22 µm)-sterilized. To 0.5 mL S9-mix components 0.5 mL S9-fraction was added (50% (v/v) S9-fraction) to complete the S9-mix. Metabolic activation was achieved by adding 0.2 mL S9-mix to 5.3 mL of a lymphocyte culture (containing 4.8 mL culture medium, 0.4 mL blood and 0.1 mL (9 mg/mL) phytohaemagglutinin)
- concentration or volume of S9 mix and S9 in the final culture medium: 1.8% (v/v) - Test concentrations with justification for top dose:
- Dose-range finding test: 31.3, 62.5, 125, 250, 500 and 1000 μg/mL (+/- S9, 3h exposure) and 62.5, 125, 250, 500, 1000 and 2000 μg/mL (- S9, 24h exposure). Precipitation was observed at dose levels of 125 μg/ml and upwards after adding the test item to the culture medium. However, the amount of precipitate decreased during incubation. After 3 h the precipitate was only observed at dose levels of 1000 μg/mL and upwards.
First cytogenetic assay: 50, 500, 750 and 1000 μg/mL (+/-S9, 3 h exposure, 27 h harvest time). Based on precipitates observed in the dose range finding experiment. Due to an error 2 dose levels were selected with precipitate, which is not according to OECD 487. Since the amount of precipitate did not interfere with the scoring and clear results were obtained this does not impact the validity of the study. In the presence of S9-mix the positive control did not give a proper response.
Therefore, the experiment was rejected and repeated in cytogenetic assay 1A with the following dose levels: 50, 500 and 750 μg/mL culture medium (+/-S9, 3 h exposure, 27 h harvest time), In this repeat experiment only one dose level was tested with precipitate.
Second cytogenetic assay: 50, 500, 750 and 1000 μg/mL culture medium (- S9, 24 h exposure, 24 h harvest time). Based on precipitates observed in the dose range finding experiment. - Vehicle / solvent:
- - Vehicle used: DMSO (Merck, Darmstadt, Germany)
- Justification for choice of vehicle: a solubility test was performed based on visual assessment. The test item formed a clear colourless solution in dimethyl sulfoxide.
- Justification for percentage of vehicle in the final culture medium: 1.0% (v/v) - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- colchicine
- cyclophosphamide
- mitomycin C
- Details on test system and experimental conditions:
- NUMBER OF REPLICATIONS:
- Number of cultures per concentration: duplicate
- Number of independent experiments 3
METHOD OF TREATMENT/ EXPOSURE:
- Test substance added in medium (0.4 mL blood was added to 5 mL or 4.8 mL culture medium, +/- S9, respectively and 0.1 mL (9 mg/mL) phytohaemagglutinin)
TREATMENT AND HARVEST SCHEDULE:
- Preincubation period: 46 ± 2 h
- Exposure duration/duration of treatment: 3h / 24h
- Harvest time after the end of treatment: 24 h
FOR MICRONUCLEUS:
- Spindle inhibitor (cytogenetic assays): 0.1 μg/mL (3 h exposure) and 0.05 μg/mL (24 h exposure) colchicin was used as a direct acting aneugen.
- If cytokinesis blocked method was used for micronucleus assay: cytochalasine B (Sigma; 5 μg/mL) was added to the culture after the end of the 3 h expsore period for 24 h (first cytogenetic assay +/- S9) or cytochalasin B (5 μg/mL) was added during the test substance exposure period to the medium for 24 h (second cytogenetic assay, -S9).
- Methods of slide preparation and staining technique used including the stain used (for cytogenetic assays): fixed slides were stained for 10 - 30 min with 5% (v/v) Giemsa (Merck) solution in Sörensen buffer pH 6.8.
- Number of cells spread and analysed per concentration: at least 2000 (with a maximum deviation of 5%) binucleated cells per concentration
- Criteria for scoring micronucleated cells (selection of analysable cells and micronucleus identification):
The following criteria for scoring of binucleated cells were used (1 - 2, 6):
- Main nuclei that were separate and of approximately equal size.
- Main nuclei that touch and even overlap as long as nuclear boundaries are able to be distinguished.
- Main nuclei that were linked by nucleoplasmic bridges.
The following cells were not scored:
- Trinucleated, quadranucleated, or multinucleated cells.
- Cells where main nuclei were undergoing apoptosis (because micronuclei may be gone already or may be caused by apoptotic process).
The following criteria for scoring micronuclei were adapted from Fenech, 1996:
- The diameter of micronuclei should be less than one-third of the main nucleus.
- Micronuclei should be separate from or marginally overlap with the main nucleus as long as there is clear identification of the nuclear boundary.
- Micronuclei should have similar staining as the main nucleus
METHODS FOR MEASUREMENT OF CYTOTOXICITY
- Method: cytostasis / cytotoxicity was determined by determination of cytokinesis-Block Proliferation Index (CBPI)
METHODS FOR MEASUREMENTS OF GENOTOXICIY
At least 2000 binucleated cells per concentration were examined by light microscopy for micronuclei. In addition, at least 2000 mononucleated cells per concentration were scored for micronuclei separately. Due to cytotoxicity the number of examined bi- or mononucleated cells in the positive control groups might be <1000.
- Evaluation criteria:
- A test item is considered positive (clastogenic or aneugenic) in the in vitro micronucleus test if all of the following criteria are met:
a) At least one of the test concentrations exhibits a statistically significant (Chi-square test, one-sided, p < 0.05) increase compared with the concurrent negative control.
b) The increase is dose-related in at least one experimental condition when evaluated with a Cochran Armitage trend test.
c) Any of the results are outside the 95% control limits of the historical control data range.
A test item is considered negative (not clastogenic or aneugenic) in the in vitro micronucleus test if:
a) None of the test concentrations exhibits a statistically significant (Chi-square test, onesided, p < 0.05) increase compared with the concurrent negative control.
b) There is no concentration-related increase when evaluated with a Cochran Armitage trend test.
c) All results are inside the 95% control limits of the negative historical control data range. - Key result
- Species / strain:
- lymphocytes:
- Remarks:
- peripheral human (3h exposure)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity, but tested up to precipitating concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Key result
- Species / strain:
- lymphocytes:
- Remarks:
- peripheral human (24 h exposure)
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 53% and 59% cytostatisis (CBPI) was reached at 750 and 1000 μg/mL, respectively. Precipitate was observed at the two highest dose levels (750 and 1000 μg/ml).
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Data on pH: 8.0 at 62 µg/mL (compared to 8.1 in the vehicle control). Since pH and osmolarity detmerination is performed at the beginning of the assay, 62.5 μg/ml was the highest non precipitating dose level, and measurements were performed at this concentration.
- Data on osmolality: 436 mOsm/kg (compared 439 mOsm/kg in the vehicle control)
- Precipitation and time of the determination:
Dose range finding test: Precipitates were observed at a concentration of 125 μg/mL and upwards after adding the test item to the culture medium. After 3h precipitate was only observed at dose levels of 750 μg/mL and upwards. Precipitates were visible at 1000 µg/mL (3h exposure, +/- S9) and 1000 and 2000 µg/mL (24 h exposure, -S9)
First cytogenetic assay: Precipitates were observed at at the two highest dose levels 750 and 1000 µg/mL (3h exposure, +/- S9) --> positive control did not give a proper response, therefore this experiment was rejected
First cytogenetic assay (1A): Precipitates were observed at the highest dose level of 750 µg/mL (3h exposure, +/- S9)
Secon cytogenetic assay: Precipitates were observed at the two highest dose levels 750 and 1000 µg/mL (24 h exposure, -S9)
- Definition of acceptable cells for analysis: 2000 cells (binucleated) / concentration
Other: First cytogenetic assay: Positive control did not give a proper response, therefore this experiment was rejected.
RANGE-FINDING/SCREENING STUDIES: a preliminary assay with 3h (+/- S9) and 24 h (-S9) exposure was performed up to an concentration of 1000/2000 µg/mL, respectively. Precipitates were observed at a concentration of 125 μg/mL and upwards after adding the test item to the culture medium. However, the amount of precipitate decreased during incubation. After 3 h the precipitate was only observed at dose levels of 750 μg/mL and upwards. Substantial toxicity (at least 55 ± 5 % cytostasisl were observed at 1000 µg/mL (3h exposure and 24 h exposure -S9) and 2000 µg/mL (24 h exposure -S9). Please refer to table 1 in the " any other information on results including tables section".
STUDY RESULTS
- Concurrent vehicle negative and positive control data : The number of mono- and binucleated cells with micronuclei found in the vehicle control cultures was within the 95% control limits of the distribution of the historical negative control database. The positive control chemicals, mitomycin C and cyclophosphamide both produced
a statistically significant increase in the number of binucleated cells with micronuclei. The positive control chemical colchicine produced a statistically significant increase in the number of mononucleated cells with micronuclei. In addition, the number of mono- and binucleated cells with micronuclei found in the positive control cultures was within the 95%
control limits of the distribution of the historical positive control database. It was therefore concluded that the test conditions were adequate and that the metabolic activation system (S9-mix) functioned properly.
For all test methods and criteria for data analysis and interpretation:
- ACCEPTABILITY CRITERIA
An in vitro micronucleus test is considered acceptable if it meets the following criteria:
a) The concurrent negative control data are considered acceptable when they are within the 95% control limits of the distribution of the historical negative control database.
b) The concurrent positive controls should induce responses that are compatible with those generated in the historical positive control database.
c) The positive control item colchicine induces a statistically significant increase in the number of mononucleated cells with micronuclei and the positive control items MMC-C and CP induces a statistically significant increase in the number of binucleated cells with
micronuclei. The positive control data will be analyzed by the Chi-square test (one-sided, p < 0.05).
d) Cell proliferation criteria in the solvent control are fulfilled to assure that sufficient treated cells have undergone mitosis during the test and that the treatments are conducted at appropriate levels of cytotoxicity.
e) All experimental conditions are tested unless one resulted in positive results.
f) Adequate number of cells and concentrations were analyzed.
g) The criteria for the selection of the top concentration are fulfilled.
Micronucleus test in mammalian cells:
- Results from cytotoxicity measurements: Substantial toxicity (at least 55 ± 5 % cytostasisl) was not observed in the first cytogenetic experiment (1A) . In the second cytogenetic assay toxicity, cytokinesis-block proliferation index of 55 ± 5% was determined at 750 and 1000 µg/mL.
- Genotoxicity results
- The test substance did not induce a statistically significant or biologically relevant increase in the number of mono- and binucleated cells with micronuclei in the absence and presence of S9-mix, in either of the two experiments.
HISTORICAL CONTROL DATA
- Positive historical control data: Mitomycin C and cyclophosphamide both produced a statistically significant increase in the number of binucleated cells with micronuclei. Colchicine produced a statistically significant increase in the
number of mononucleated cells with micronuclei. In addition, the number of mono- and binucleated cells with micronuclei found in the positive control cultures was within the 95% control limits of the distribution of the historical positive control database. Please refer to table 13 in the " any other information on results including tables section".
- Negative (vehicle) historical control data: The number of mono- and binucleated cells with micronuclei found in the vehicle control was within the 95% control limits of the distribution of the historical negative control database. Please refer to table 12 in the " any other information on results including tables section". - Remarks on result:
- other: Under the conditions of the conducted test, the test substance did not induce a statistically significant or biologically relevant increase in the number of mono- and binucleated cells with micronuclei in the absence and presence of S9.
- Conclusions:
- Under the conditions of the conducted test, the test substance did not induce a statistically significant or biologically relevant increase in the number of mono- and binucleated cells with micronuclei in the absence and presence of S9.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 11 March - 30 April 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 490 (In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene)
- Version / remarks:
- adopted 29 July 2016
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian cell gene mutation tests using the thymidine kinase gene
- Target gene:
- thymidine kinase gene
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- CELLS USED
- Type and source of cells: American Type Culture Collection, (ATCC, Manassas, USA, 2001)
- Suitability of cells: recommended cell line according to OECD TG 490
For cell lines:
- Absence of Mycoplasma contamination: yes
- Periodically ‘cleansed’ of spontaneous mutants: yes
MEDIA USED
- Type and composition of media, CO2 concentration, humidity level, temperature: 5.0 ± 0.5% CO2, humid atmosphere (80 - 100%, actual range 24 - 98%), 37.0 ± 1.0°C (actual range 34.3 - 38.5 °C).
Basic medium
RPMI 1640 Hepes buffered medium (Dutch modification) (Life Technologies) containing penicillin/streptomycin (50 U/mL and 50 μg/mL, respectively) (Life Technologies), 1 mM sodium pyruvate (Sigma, Zwijndrecht, The Netherlands) and 2 mM L-glutamin (Life Technologies).
Growth medium
Basic medium, supplemented with 10% (v/v) heat-inactivated horse serum (=R10 medium).
Exposure medium
For 3 hour exposure: Cells were exposed to the test item in basic medium supplemented with 5% (v/v) heat-inactivated horse serum (R5-medium).
For 24 hour exposure: Cells were exposed to the test item in basic medium supplemented with 10% (v/v) heat-inactivated horse serum (R10-medium).
Selective medium
Selective medium consisted of basic medium supplemented with 20% (v/v) heat-inactivated horse serum (total amount of serum = 20%, R20-medium) and 5 μg/mL trifluorothymidine (TFT) (Sigma).
Non-selective medium
Non-selective medium consisted of basic medium supplemented with 20% (v/v) heat-inactivated horse serum (total amount of serum = 20%, R20-medium).
Horse serum
Horse serum (Life Technologies) was inactivated by incubation at 56°C for at least 30 minutes. - Metabolic activation:
- with and without
- Metabolic activation system:
- Type and composition of metabolic activation system:
- source of S9 : Rat liver microsomal enzymes (S9 homogenate) (Trinova Biochem GmbH, Giessen, Germany) and was prepared from male Sprague Dawley rats that have been dosed orally with a suspension of phenobarbital (80 mg/kg body weight) and ß-naphthoflavone (100 mg/kg body weight).
- method of preparation of S9 mix: S9-mix was prepared immediately before use and kept refrigerated. S9-mix components contained per mL physiological saline: 1.63 mg MgCl2.6H2O (Merck); 2.46 mg KCl (Merck); 1.7 mg glucose-6-phosphate (Roche, Mannheim, Germany); 3.4 mg NADP (Randox Laboratories Ltd., Crumlin, United Kingdom); 4 μmol HEPES (Life technologies). The above solution was filter (0.22 μm)-sterilized. To 0.5 mL S9-mix components 0.5 mL S9-fraction was added (50% (v/v) S9-fraction) to complete the S9-mix.
- concentration of S9 mix in the final culture medium: 4% - Test concentrations with justification for top dose:
- Dose-range-finding test (3 h and 24 h exposure): 63, 125, 250, 500, 600, 700, 800, 900 and 1000 μg/mL (3h, +/- S9 and 24h, -S9). The test item precipitated in the exposure medium at concentrations of 1000 μg/mL and
above. Therefore, 1000 µg/mL was used as the highest test item concentration in the dose range finding test.
Cytotoxicity, determined by relative suspension growth was 74% at 500 μg/mL compared to the relative suspension growth of the solvent control. No cell survival was observed at the test item concentration of 1000 μg/mL (3h, - S9). No toxicity in the relative suspension growth was observed up to test item concentrations of 1000 μg/mL compared to the vehicle control (3h, +S9). The relative suspension growth was 37% at the test item concentration of 1000 μg/mL compared to the relative suspension growth of the vehicle control (24h, -S 9).
First mutagenicity test (3 h exposure): 16, 31, 63, 125, 250, 500, 600, 700, 800, 900 and 1000 μg/mL (- S9) and 7.8, 16, 31, 63,125, 250, 500 and 1000 μg/mL (+ S9). Doses selected based on results of the dose-range-finding test.
Second mutagenicity test (24 h exposure): 7.8, 16, 31, 63, 125, 250, 500 and 700 μg/mL (- S9). Doses selected based on results of the dose-range-finding test. - Vehicle / solvent:
- - Vehicle used: DMSO
- Justification for choice of solvent/vehicle: A solubility test was performed based on visual assessment. The test item formed a clear colourless solution in dimethyl sulfoxide.
- Justification for percentage of solvent in the final culture medium: 1% (v/v) - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- methylmethanesulfonate
- Details on test system and experimental conditions:
- NUMBER OF REPLICATIONS:
- Number of cultures per concentration: 5 wells with mutants per selection plate
- Number of independent experiments : 2
METHOD OF TREATMENT/ EXPOSURE:
- Test substance added in medium; cell cultures were exposed to the test item in exposure medium in the absence as well as in the presence of S9-mix
TREATMENT AND HARVEST SCHEDULE:
- Exposure duration/duration of treatment: 3h/24h
FOR GENE MUTATION:
- Expression time: 2 days
- Selection time: 11/12 days
- Method used: microwell plates
- Selective agent used: 5 μg/mL trifluorothymidine (Sigma)
- Number of cells seeded and method to enumerate numbers of viable and mutants cells: 9.6 x 105 cells per concentration were plated in five 96-well microtiter plates for determination of mutation frequency
- Criteria for small (slow growing) and large (fast growing) colonies: The small colonies are morphologically dense colonies with a sharp contour and with a diameter less than a quarter of a well. The large colonies are morphologically less dense colonies with a hazy contour and with a diameter larger than a quarter of a well. A well containing more than one small colony is classified as one small colony. A well containing more than one large colony is classified as one large colony. A well containing one small and one large colony is classified as one large colony.
METHODS FOR MEASUREMENT OF CYTOTOXICITY
- Method: relative total growth (RTG) / relative survival (RS)
METHODS FOR MEASUREMENTS OF GENOTOXICIY
- Increase in mutation frequency - Evaluation criteria:
- - For the micro well version of the assay the GEF is 126 x 10-6.
- A test item is considered positive (mutagenic) in the mutation assay if it induces a MF of more than MF(controls) + 126 in a dose-dependent manner. An observed increase should be biologically relevant and will be compared with the historical control data range.
- A test item is considered equivocal (questionable) in the mutation assay if no clear conclusion for positive or negative result can be made after an additional confirmation study.
- A test item is considered negative (not mutagenic) in the mutation assay if: none of the tested concentrations reaches a mutation frequency of MF(controls) + 126. - Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Remarks:
- 3 h exposure
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- RTG (%) was 88, 90, 38 and 20 at concentrations of 500, 600, 700 and 800 µg/mL, resepctively (-S9) and 89, 93 and 82 at concentrations of 250, 500 and 1000 µg/mL, resepctively (+S9). Precipitates: 700 and 800 µg/mL (-S9) and 1000 µg/mL (+S9).
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Remarks:
- 24 h exposure
- Metabolic activation:
- without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- RTG% was 74, 77 and 52 at concentrations of 250, 500 and 700 µg/mL, respectively. Precipitates: 700 µg/mL.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- True negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Precipitation and time of the determination: The test item precipitated in the exposure medium at concentrations of 700 and 800 µg/mL (3 h, - S9), 1000 µg/mL (3 h, +S9) and 700 µg/mL (24 h, -S9)
RANGE-FINDING/SCREENING STUDIES: In the dose-range finding test, L5178Y mouse lymphoma cells were treated with the test item (concentration range of 63 to 1000 μg/mL) in the absence of S9-mix with 3 and 24 h exposure and in the presence of S9-mix with a 3 h exposure. The test item precipitated in the exposure medium at concentrations of 1000 μg/mL and above. Therefore, 1000 µg/mL was used as the highest test item concentration in the dose range finding test. Cytotoxicity, determined by relative suspension growth was 74% at 500 μg/mL compared to the relative suspension growth of the solvent control. No cell survival was observed at the test item concentration of 1000 μg/mL (3h, - S9). No toxicity in the relative suspension growth was observed up to test item concentrations of 1000 μg/mL compared to the vehicle control (3h, +S9). The relative suspension growth was 37% at the test item concentration of 1000 μg/mL compared to the relative suspension growth of the vehicle control (24h, -S 9).
STUDY RESULTS
- Concurrent vehicle negative and positive control data : The mutation frequency found in the vehiclet control cultures was within the acceptability criteria of this assay and within the 95% control limits of the distribution of the historical
negative control database. Positive control chemicals, methyl methanesulfonate and cyclophosphamide, both produced significant increases in the mutation frequency. In addition, the mutation frequency found in the positive control cultures was within the 95% control limits of the distribution of the historical positive control database.
For all test methods and criteria for data analysis and interpretation:
- Any other criteria: For the micro well version of the assay the GEF is 126 x 10-6.
- A test item is considered positive (mutagenic) in the mutation assay if it induces a MF of more than MF(controls) + 126 in a dose-dependent manner. An observed increase should be biologically relevant and will be compared with the historical control data range.
- A test item is considered equivocal (questionable) in the mutation assay if no clear conclusion for positive or negative result can be made after an additional confirmation study.
- A test item is considered negative (not mutagenic) in the mutation assay if: none of the tested concentrations reaches a mutation frequency of MF(controls) + 126.
A mutation assay was considered acceptable if it met the following criteria:
a) The absolute cloning efficiency of the solvent controls (CEday2) is between 65 and 120% in order to have an acceptable number of surviving cells analyzed for expression of the TK mutation.
b) The spontaneous mutation frequency in the solvent control is ≥ 50 per 106 survivors and ≤ 170 per 106 survivors.
c) The suspension growth (SG) over the 2-day expression period for the solvent controls should be between 8 and 32 for the 3 hour treatment, and between 32 and 180 for the 24 hour treatment.
d) The positive control should demonstrate an absolute increase in the total mutation frequency, that is, an increase above the spontaneous background MF (an induced MF (IMF)) of at least 300 x 10-6. At least 40% of the IMF should be reflected in the small colony MF. And/or, the positive control has an increase in the small colony MF of at least 150 x 10-6 above that seen in the concurrent solvent control (a small colony IMF of 150 x 10-6).
e) The upper limit of cytotoxicity observed in the positive control culture should be the same as of the experimental cultures. That is, the RTG/RS should not be less than 10%.The MF of the positive control must be within the acceptable range established for the laboratory
f) Two experimental conditions (short treatment with and without metabolic activation) were conducted unless one resulted in positive results.
g) Adequate number of cells and concentrations should be analysable
h) The criteria for the selection of top concentration are consistent with those described in OECD Guideline 490
Gene mutation tests in mammalian cells:
- Results from cytotoxicity measurements: First mutagenicity test: RTG (%) was 88, 90, 38 and 20 at concentrations of 500, 600, 700 and 800 µg/mL, resepctively (-S9) and 89, 93 and 82 at concentrations of 250, 500 and 1000 µg/mL, resepctively (+S9). Dose levels of 16 to 250 μg/mL showed no cytotoxicity (3h, -S9). The dose levels of 900 and 1000 μg/mL were not used for mutation frequency measurement, since these dose levels were too toxic for further testing. Second mutagenicity test: RTG% was 74, 77 and 52 at concentrations of 250, 500 and 700 µg/mL, respectively.
- Genotoxicity results:
o Concentrations selected for evaluation based on toxicity: First mutagenicity test: 31, 63, 125, 250, 500, 600, 700 and 800 μg/mL (3h, -S9), 7.8, 16, 31, 63, 125, 250, 500 and 1000 μg/mL (3h, +S9) In the presence of S9-mix, no significant toxicity was observed and all dose levels were evaluated. Second mutagenicity test: 7.8, 16, 31, 63, 125, 250, 500, 600 and 700 μg/mL (24h, -S9). No severe toxicity was observed up to and including the highest tested dose level and all dose levels were evaluated
o Number of cells treated and sub-cultures for each cultures : Per culture 8 x 106 cells (106 cells/mL for 3 hour treatment) or 6 x 106 cells (1.25 x 105 cells/mL for 24 hour treatment) (Treatment of cells)
o Number of cells plated in selective and non-selective medium : 9.6 x 105 cells per concentration were plated in five 96-well microtiter plates, each well containing 2000 cells in selective medium
HISTORICAL CONTROL DATA
- Positive historical control data: Please refer to table 9 in the " any other information on results including tables section".
- Negative (vehicle) historical control data: Please refer to table 8 in the " any other information on results including tables section". - Conclusions:
- Under the conditions of the conducted test the substance did not induce forward muatation inthe thymidine kinase gene in L5178Y TK+/- 3.7.2C mouse lymphoma cells with and without metabolic activation.
Referenceopen allclose all
Table 1: Numbers of revertant colonies in the preliminary toxicity test
With (+) or without (-) S9-mix | Strain | Dose (µ/plate) | ||||||||||
0 | 0.15 | 0.5 | 1.5 | 5 | 15 | 50 | 150 | 500 | 1500 | 5000 | ||
- | TA 100 | 90 | 88 | 99 | 108 | 113 | 114 | 107 | 86 | 114 | 118 | 113* |
+ | TA 100 | 120 | 112 | 108 | 121 | 100 | 98 | 92 | 96 | 90 | 98 | 105* |
- | WP2 uvrA- | 43 | 40 | 40 | 43 | 48 | 42 | 38 | 38 | 45 | 41 | 42* |
+ | WP2 uvrA- | 47 | 43 | 48 | 43 | 38 | 37 | 42 | 41 | 37 | 38 | 42* |
* Precipitate present
Table 2: Range-finding test without metabolic activation
Revertant colony counts (mean of 3 replicates) | |||||
Test substance concentration (µg/plate) | TA 100 | TA 1535 | WP2 uvrA- | TA98 | TA1537 |
0 | 105 | 19 | 28 | 24 | 13 |
50 | 111 | 16 | 24 | 25 | 10 |
150 | 120 | 14 | 28 | 29 | 12 |
500 | 105 | 15 | 31 | 25 | 11 |
1500 | 109P | 17P | 26P | 28P | 12P |
5000 | 115P | 14P | 30P | 24P | 13P |
ENNG (3) | 497 | ||||
ENNG (5) | 162 | ||||
ENNG (2) | 283 | ||||
4NQO (0.2) | 116 | ||||
9AA (80) | 2530 |
P - precipitate
Abbreviations: ENNG, N-ethyl-N’-nitro-N-nitrosoguanidine; 9AA, 2-aminoacridine; BP, benzo(a)pyrene; 2AA, 2-aminoanthracene; 4NQO, 4- nitroquinoline-1-oxide
Table 3: Range-finding test with metabolic activation
Revertant colony counts (mean 3 replicates) | |||||
Test substance concentration (µg/plate) | TA 100 | TA 1535 | WP2 uvrA- | TA98 | TA1537 |
0 | 115 | 14 | 33 | 29 | 12 |
50 | 98 | 13 | 32 | 27 | 12 |
150 | 109 | 16 | 32 | 30 | 11 |
500 | 99 | 10 | 29 | 29 | 12 |
1500 | 115P | 14P | 31P | 29P | 12P |
5000 | 116P | 14P | 32P | 29P | 14P |
2AA (1) | 801 | ||||
2AA (2) | 292 | 95 | |||
2AA (10) | 130 | ||||
BP (5) | 189 |
P - preicipitate
Table 4: Main Test without metabolic activation
Revertant colony counts (mean 3 replicates) | |||||
Test substance concentration (µg/plate) | TA 100 | TA 1535 | WP2 uvrA- | TA98 | TA1537 |
0 | 117 | 21 | 26 | 34 | 9 |
50 | 115 | 20 | 35 | 27 | 11 |
150 | 117 | 20 | 30 | 27 | 9 |
500 | 115 | 21 | 31 | 30 | 10 |
1500 | 117P | 20P | 31P | 31P | 11P |
5000 | 124P | 18P | 30P | 32P | 7P |
ENNG (3) | 439 | ||||
ENNG (5) | 174 | ||||
ENNG (2) | 182 | ||||
4NQO (0.2) | 122 | ||||
9AA (80) | 730 |
P - precipitate.
Table 5: Main Test with metabolic activation
Revertant colony counts (mean 3 replicates) | |||||
Test substance concentration (µg/plate) | TA 100 | TA 1535 | WP2 uvrA- | TA98 | TA1537 |
0 | 124 | 24 | 41 | 29 | 13 |
50 | 117 | 18 | 38 | 24 | 10 |
150 | 127 | 18 | 36 | 30 | 9 |
500 | 119 | 11 | 34 | 33 | 12 |
1500 | 114P | 13P | 29P | 26P | 10P |
5000 | 130P | 18P | 35P | 22P | 9P |
2AA (1) | 952 | ||||
2AA (2) | 261 | 217 | |||
2AA (10) | 202 | ||||
BP (5) | 309 |
P - precipitate
Table 1: Cytokinesis-block proliferation index of human lymphocyte cultures in the dose-range finding test
Without metabolic activation (-S9-mix) |
|||||
3 hours exposure time, 27 hours harvest time |
|||||
Concentration µg/mL |
Number of cells with ….nuclei |
CBPI |
% cytostasis |
||
1 |
2 |
3 or more |
|||
0 (vehicle) |
325 |
169 |
11 |
1.38 |
0 |
31.3 |
328 |
159 |
13 |
1.37 |
2 |
62.5 |
368 |
124 |
8 |
1.28 |
26 |
125 |
365 |
125 |
10 |
1.29 |
23 |
250 |
365 |
133 |
2 |
1.27 |
28 |
500 |
392 |
111 |
4 |
1.23 |
38 |
10001) |
417 |
80 |
3 |
1.17 |
55 |
With metabolic activation (+S9-mix) |
|||||
3 hours exposure time, 27 hours harvest time |
|||||
Concentration µg/mL |
Number of cells with ….nuclei |
CBPI |
% cytostasis |
||
1 |
2 |
3 or more |
|
|
|
0 (vehicle) |
328 |
157 |
15 |
1.37 |
0 |
31.3 |
342 |
147 |
11 |
1.34 |
10 |
62.5 |
341 |
144 |
15 |
1.35 |
7 |
125 |
363 |
132 |
5 |
1.28 |
24 |
250 |
381 |
112 |
8 |
1.26 |
32 |
500 |
385 |
107 |
8 |
1.25 |
34 |
10001) |
399 |
98 |
3 |
1.21 |
44 |
With metabolic activation (-S9-mix) |
|||||
24 hours exposure time, 24 hours harvest time |
|||||
Concentration µg/mL |
Number of cells with ….nuclei |
CBPI |
% cytostasis |
||
|
1 |
2 |
3 or more |
|
|
0 (vehicle) |
327 |
155 |
18 |
1.38 |
0 |
62.5 |
364 |
128 |
8 |
1.29 |
25 |
125 |
347 |
156 |
9 |
1.34 |
11 |
250 |
331 |
162 |
7 |
1.35 |
8 |
500 |
383 |
117 |
0 |
1.23 |
39 |
10001) |
409 |
91 |
0 |
1.18 |
52 |
20001) |
484 |
16 |
0 |
1.03 |
92 |
Note: All calculations were performed without rounding off.
1)The test item precipitated in the culture medium
Table 2: Cytokinesis-block proliferation index of human lymphocytes cultures in the first cytogenetic assay
Without metabolic activation (-S9-mix) |
|||||
3 hours exposure time, 27 hours harvest time |
|||||
Concentration µg/mL |
CBPI |
Mean CBPI |
% cytostasis |
||
0 (vehicle) |
1.27 |
- |
1.45 |
1.36 |
0 |
50 |
1.24 |
- |
1.25 |
1.25 |
31 |
500 |
1.24 |
- |
1.28 |
1.26 |
27 |
7501) |
1.27 |
- |
1.29 |
1.28 |
22 |
10001) |
1.24 |
- |
1.27 |
1.26 |
29 |
0.25 MMC-C |
1.20 |
- |
1.21 |
1.20 |
43 |
0.38 MMC-C |
1.18 |
- |
1.20 |
1.19 |
47 |
0.1 Colchicin |
1.04 |
- |
1.04 |
1.04 |
90 |
With metabolic activation (+S9-mix) |
|||||
3 hours exposure time, 27 hours harvest time |
|||||
Concentration µg/mL |
CBPI |
CBPI |
% cytostasis |
||
0 (vehicle) |
1.35 |
- |
1.36 |
1.36 |
0 |
50 |
1.30 |
- |
1.31 |
1.31 |
14 |
500 |
1.28 |
- |
1.38 |
1.33 |
7 |
7501) |
1.28 |
- |
1.35 |
1.31 |
12 |
10001) |
1.29 |
- |
1.30 |
1.30 |
17 |
15 CP |
1.24 |
- |
1.37 |
1.30 |
15 |
15 CP |
1.32 |
- |
1.33 |
1.33 |
9 |
Note: All calculations were performed without rounding off. CP:CyclophosphamideMMC-C: Mitomycin C
1)The test item precipitated in the culture medium
Table 3: Cytokinesis-block proliferation index of human lymphocytes cultures in cytogenetic assay 1a
With metabolic activation (+ S9-mix) |
||||
3 hours exposure time, 27 hours harvest time |
||||
Concentration µg/mL |
CBPI |
Mean CBPI |
% cytostasis |
|
0 (vehicle) |
1.27 - 1.42 |
1.35 |
0 |
|
50 |
1.39 -1.39 |
1.39 |
-13 |
|
500 |
1.25 - 1.27 |
1.26 |
24 |
|
7501) |
1.21 - 1.32 |
1.27 |
22 |
|
15 CP |
1.13 - 1.16 |
1.15 |
58 |
|
17.5 CP |
1.10 - 1.14 |
1.12 |
65 |
Note: All calculations were performed without rounding off. CP:Cyclophosphamide
1)The test item precipitated in the culture medium
Table 4: Number of mononucleated or binucleated cells with micronuclei of human lymphocyte cultures in the first cytogenetic assay
Without metabolic activation (-S9-mix) |
|||||||
3 hours exposure time, 27 hours harvest time |
|||||||
Concentration (µg/mL) |
Cytostasis (%) |
Number of mononucleated cells with micronuclei 1) |
Number of binucleated cells with micronuclei 1) |
||||
1000 |
1000 |
2000 |
1000 |
1000 |
2000 |
||
A |
B |
A+B |
A |
B |
A+B |
||
0 (vehicle) |
0 |
0 |
0 |
0 |
0 |
3 |
3 |
500 |
27 |
0 |
0 |
0 |
1 |
3 |
4 |
750 |
22 |
0 |
0 |
0 |
0 |
2 |
2 |
1000 |
29 |
0 |
0 |
0 |
2 |
2 |
4 |
0.25-C |
43 |
0 |
1 |
1 |
7 |
7 |
14** |
0.38-C |
47 |
1 |
0 |
1 |
13 |
9 |
22*** |
0.1 Colch |
90 |
28 |
20 |
48*** |
36 |
42 |
78*** |
CP:CyclophosphamideMMC-C: Mitomycin C
Table 5: Number of mononucleated or binucleated cells with micronuclei of human lymphocyte cultures in cytogenetic assay 1a
With metabolic activation (+S9-mix) |
|||||||
3 hours exposure time, 27 hours harvest time |
|||||||
Concentration (µg/mL) |
Cytostasis (%) |
Number of mononucleated cells with micronuclei1) |
Number of binucleated cells with micronuclei1) |
||||
1000 |
1000 |
2000 |
1000 |
1000 |
2000 |
||
A |
B |
A+B |
A |
B |
A+B |
||
0 (vehicle) |
0 |
0 |
0 |
0 |
2 |
0 |
2 |
50 |
-13 |
1 |
0 |
1 |
2 |
1 |
3 |
500 |
24 |
0 |
0 |
0 |
0 |
2 |
2 |
750 |
22 |
0 |
0 |
0 |
2 |
1 |
3 |
15 CP |
58 |
1 |
2 |
3* |
20 |
15 |
35*** |
CP:CyclophosphamideMMC-C: Mitomycin C
*) Significantly different from control group (Chi-square test), * P < 0.05, ** P < 0.01 or *** P < 0.001.
1) 1000 bi- and mononucleated cells were scored for the presence of micronuclei.
Duplicate cultures are indicated by A and B.
Table 6: Cytokinesis-block proliferation index of human lymphocyte cultures in the second cytogenetic assay
Without metabolic activation (-S9-mix) |
||||||
24 hours exposure time, 24 hours harvest time |
||||||
Concentration µg/mL |
CBPI |
Mean CBPI |
% cytostasis |
|||
0 (vehicle) |
1.34 |
- |
1.34 |
1.34 |
0 |
|
50 |
1.31 |
- |
1.32 |
1.32 |
7 |
|
500 |
1.25 |
- |
1.30 |
1.28 |
19 |
|
7501) |
1.15 |
- |
1.17 |
1.16 |
53 |
|
10001) |
1.14 |
- |
1.14 |
1.14 |
59 |
|
0.15 MMC-C |
1.12 |
- |
1.14 |
1.13 |
62 |
|
0.23 MMC-C |
1.11 |
- |
1.11 |
1.11 |
68 |
|
0.05 Colchicin |
1.00 |
- |
1.01 |
1.00 |
99 |
CP:CyclophosphamideMMC-C: Mitomycin C Note: All calculations were performed without rounding off.
1)The test item precipitated in the culture medium
Table 7: Number of mononucleated or binucleated cells with micronuclei of human lymphocyte cultures in the second cytogenetic assay
Without metabolic activation (-S9-mix) |
|||||||
24 hours exposure time, 24 hours harvest time |
|||||||
Concentration (µg/mL) |
Cytostasis (%) |
Number of mononucleated cells with micronuclei 1) |
Number of binucleated cells with micronuclei 1) |
||||
1000 |
1000 |
2000 |
1000 |
1000 |
2000 |
||
A |
B |
A+B |
A |
B |
A+B |
||
0 (vehicle) |
0 |
2 |
1 |
3 |
2 |
2 |
4 |
50 |
7 |
2 |
0 |
2 |
2 |
3 |
5 |
500 |
19 |
1 |
0 |
1 |
0 |
4 |
4 |
750 |
53 |
1 |
2 |
3 |
4 |
4 |
8 |
0.15-C |
62 |
1 |
1 |
2 |
19 |
17 |
36*** |
0.05 Colchicin |
99 |
18 |
20 |
38*** |
22) |
12) |
3 |
CP:CyclophosphamideMMC-C: Mitomycin C
*) Significantly different from control group (Chi-square test), * P < 0.05, ** P < 0.01 or *** P < 0.001.
1) 1000 bi- and mononucleated cells were scored for the presence of micronuclei.
Duplicate cultures are indicated by A and B.
2) 365 and 275 binucleated cells were scored for the presence of micronuclei, respectively.
Table 8: Scoring of cells with one, two or more nuclei of human lymphocyte cultures in the first cytogenetic assay
Without metabolic activation (-S9-mix) |
|||||
3 hours exposure time, 27 hours harvest time |
|||||
Concentration µg/mL |
Culture |
Number of cells with ….nuclei |
CBPI |
||
1 |
2 |
3 or more |
|||
0 (vehicle) |
A |
375 |
117 |
8 |
1.27 |
B |
280 |
213 |
7 |
1.45 |
|
50
|
A |
382 |
115 |
3 |
1.24 |
B |
378 |
117 |
5 |
1.25 |
|
500
|
A |
380 |
118 |
2 |
1.24 |
B |
365 |
130 |
5 |
1.28 |
|
750
|
A |
364 |
135 |
1 |
1.27 |
B |
357 |
141 |
2 |
1.29 |
|
1000
|
A |
381 |
119 |
0 |
1.24 |
B |
364 |
136 |
0 |
1.27 |
|
0.25 MMC-C
|
A |
399 |
101 |
0 |
1.20 |
B |
397 |
103 |
0 |
1.21 |
|
0.38 MMC-C
|
A |
408 |
92 |
0 |
1.18 |
B |
400 |
100 |
0 |
1.20 |
|
0.1 Colch
|
A |
484 |
14 |
2 |
1.04 |
B |
483 |
16 |
1 |
1.04 |
|
With metabolic activation (+S9-mix) |
|||||
3 hours exposure time, 27 hours harvest time |
|||||
Concentration µg/mL |
Culture |
Number of cells with ….nuclei |
CBPI |
||
1 |
2 |
3 or more |
|||
0 (vehicle) |
A |
336 |
166 |
7 |
1.35 |
B |
324 |
171 |
5 |
1.36 |
|
50 |
A |
348 |
147 |
5 |
1.31 |
B |
351 |
146 |
3 |
1.30 |
|
500 |
A |
359 |
140 |
1 |
1.28 |
B |
313 |
184 |
3 |
1.38 |
|
750 |
A |
365 |
132 |
3 |
1.28 |
B |
328 |
168 |
4 |
1.35 |
|
1000 |
A |
353 |
147 |
0 |
1.29 |
B |
352 |
147 |
1 |
1.30 |
|
15 CP |
A |
385 |
112 |
3 |
1.24 |
B |
316 |
183 |
1 |
1.37 |
|
17.5 CP |
A |
338 |
160 |
2 |
1.33 |
B |
342 |
155 |
3 |
1.32 |
CP:CyclophosphamideMMC-C: Mitomycin C
Table 9: Scoring of cells with one, two or more nuclei of human lymphocyte cultures in cytogenetic assay 1a
With metabolic activation (+S9-mix) |
|||||
3 hours exposure time, 27 hours harvest time |
|||||
Concentration µg/mL |
Culture |
Number of cells with ….nuclei |
CBPI |
||
1 |
2 |
3 or more |
|||
0 (vehicle) |
A |
368 |
127 |
5 |
1.27 |
B |
298 |
196 |
6 |
1.42 |
|
50
|
A |
324 |
188 |
7 |
1.39 |
B |
312 |
182 |
6 |
1.39 |
|
500
|
A |
368 |
129 |
3 |
1.27 |
B |
381 |
111 |
8 |
1.25 |
|
750
|
A |
399 |
95 |
6 |
1.21 |
B |
344 |
151 |
5 |
1.32 |
|
15 CP
|
A |
419 |
81 |
0 |
1.16 |
B |
436 |
64 |
0 |
1.13 |
|
17.5 CP
|
A |
430 |
70 |
0 |
1.14 |
B |
450 |
50 |
0 |
1.10 |
CP:CyclophosphamideMMC-C: Mitomycin C
Table 10: Scoring of cells with one, two or more nuclei of human lymphocyte cultures in the second cytogenetic assay
Without metabolic activation (-S9-mix) |
|||||
24 hours exposure time, 24 hours harvest time |
|||||
Concentration µg/mL |
Culture |
Number of cells with ….nuclei |
CBPI |
||
1 |
2 |
3 or more |
|||
0 (vehicle) |
A |
338 |
154 |
8 |
1.34 |
B |
344 |
141 |
15 |
1.34 |
|
50
|
A |
347 |
145 |
8 |
1.32 |
B |
351 |
141 |
8 |
1.31 |
|
500
|
A |
356 |
139 |
5 |
1.30 |
B |
378 |
117 |
5 |
1.25 |
|
750
|
A |
425 |
75 |
0 |
1.15 |
B |
417 |
81 |
2 |
1.17 |
|
1000
|
A |
430 |
69 |
1 |
1.14 |
B |
433 |
66 |
1 |
1.14 |
|
0.15 MMC-C
|
A |
433 |
66 |
1 |
1.14 |
B |
438 |
62 |
0 |
1.12 |
|
0.23 MMC-C
|
A |
446 |
54 |
0 |
1.11 |
B |
446 |
54 |
0 |
1.11 |
|
0.05 Colchicin
|
A |
497 |
3 |
0 |
1.01 |
B |
499 |
1 |
0 |
1.00 |
CP:CyclophosphamideMMC-C: Mitomycin C
Table 11: Total number of cells with micronuclei; treatment/control comparison (mononucleated/binucleated cells)1)
Exposure |
S9-Mix |
Nucleated |
p-value |
Decision at 95% |
Dose µg/mL |
|
|
one-sided |
confidence interval |
First cytogenetic assay (Chi-square test) |
||||
3 h exposure |
|
|
|
|
MMC-C (0.25) |
- |
bi |
= 0.0038 |
significant |
MMC-C (0.38) |
- |
bi |
<0.0001 |
significant |
Colch (0.1) |
- |
mono |
<0.0001 |
significant |
Colch (0.1) |
- |
bi |
<0.0001 |
significant |
CP (15) |
+ |
mono |
= 0.0416 |
significant |
CP (15) |
+ |
bi |
<0.0001 |
significant |
Second cytogenetic assay (Chi-square test) |
||||
24 h exposure |
|
|
|
|
MMC-C (0.15) |
- |
bi |
<0.0001 |
significant |
Colchicin (0.05) |
- |
mono |
<0.0001 |
significant |
1) Only statistically significant results are presented CP:CyclophosphamideMMC-C: Mitomycin C
Table 12: Historical control data for in vitro micronucleus studies of the solvent control
|
Mononucleated |
Binucleated |
||||
|
+ S9-mix |
- S9-mix |
+ S9-mix |
- S9-mix |
||
|
3 hour exposure |
3 hour exposure |
24 hour exposure |
3 hour exposure |
3 hour exposure |
24 hour exposure |
Mean number of micronucleated cells |
0.83 |
1.00 |
0.86 |
3.67 |
3.57 |
3.58 |
SD |
0.95 |
1.01 |
1.12 |
2.53 |
2.20 |
2.51 |
n |
112 |
114 |
110 |
112 |
114 |
110 |
Upper control limit (95% control limits) |
2.85 |
3.37 |
3.60 |
9.42 |
8.94 |
9.64 |
Lower control limit (95% control limits) |
-1.19 |
-1.38 |
-1.87 |
-2.08 |
-1.79 |
-2.48 |
SD = Standard deviation
n = Number of observations
Distribution historical negative control data from experiments using different vehicles e.g. DMSO, however these vehicles never influence the number of micronucleated cells) between October 2014 and October 2017.
Table 13: Historical Control Data for in vitro Micronucleus Studies of the Positive Control Substances
|
Mononucleated |
Binucleated |
|||
|
- S9-mix |
+ S9-mix |
- S9-mix |
||
|
3 hour exposure (Colchicin) |
24 hour exposure (Colchicin) |
3 hour exposure (CP) |
3 hour exposure (MMC-C) |
24 hour exposure (MMC-C) |
Mean number of micronucleated cells (per 1000 cells) |
15.51 |
17.54 |
20.40 |
24.90 |
24.59 |
SD |
16.52 |
21.30 |
8.54 |
20.69 |
22.65 |
n |
234 |
230 |
122 |
234 |
230 |
Upper control limit (95% control limits) |
57.06 |
65.59 |
37.20 |
59.48 |
69.14 |
Lower control limit (95% control limits) |
-26.03 |
-30.51 |
3.59 |
-9.68 |
-19.97 |
SD = Standard deviation
n = Number of observations
Distribution historical positive control data from experiments performed between October 2014 and October 2017. CP:CyclophosphamideMMC-C: Mitomycin C
Table 1: Dose-range finding test: Cytotoxicity of the test item (3 h and 24 treatment)
Dose |
cell count after 24 h of subculture (cells/ml x105)
|
cell count after 48 h of subculture (cells/ml x105) |
SG(1)
|
RSG(2)
|
(μg/ml)
|
|
|
|
(%) |
3h, without metabolic activation |
||||
SC |
5.2 |
7.3 |
19 |
100 |
63 |
5.8 |
6.8 |
20 |
103 |
125 |
5.3 |
7.1 |
19 |
98 |
250 |
5.6 |
7.0 |
20 |
103 |
500 |
4.3 |
6.5 |
14 |
74 |
1000(3) |
0.1(4) |
0.4 |
0 |
0 |
3h, with metabolic activation |
||||
SC |
3.7 |
5.4 |
10 |
100 |
63 |
3.5 |
6.9 |
12 |
121 |
125 |
2.3 |
5.8 |
7 |
67 |
250 |
4.0 |
6.1 |
12 |
121 |
500 |
4.6 |
5.4 |
12 |
123 |
1000(3) |
3.5 |
5.7 |
10 |
100 |
24h, without metabolic activation |
||||
SC |
11.1 |
5.7 |
41 |
100 |
63 |
11.5 |
6.2 |
45 |
112 |
125 |
10.6 |
6.3 |
43 |
105 |
250 |
9.3 |
6.3 |
38 |
93 |
500 |
8.8 |
6.2 |
35 |
86 |
1000(3) |
3.7 |
6.3 |
15 |
37 |
Note: all calculations were made without rounding off
SC = solvent control = DMSO
(1) = suspension growth
(2) = relative suspension growth
(3) = the test item precipitated in the exposure medium
(4) = since less than 1.25 x 105 c/ml were present, no subculture was performed
3h exposure:SG = Suspension growth = [Cell count after 24 hour of subculture (Day 1) /1.6 x 105] x [Cell count after 48 hours of subculture (Day 2)/1.25 x 105]*
24 h exposure: SG = Suspension growth = [Day 0 cell count/1.25 x 105 ] x [Day 1 cell count/1.25 x 105 ]
* Or appropriate cell concentration
RSG = [SG(test)/SG(control)] x 100
Table 2: Experiment 1: Cytotoxic and mutagenic response of the test substance in the mouse lymphoma l5178Y test system
Dose |
RSG |
CE day2 |
RCE |
RTG |
Mutation frequency per 106survivors |
||
(µg/mL) |
(%) |
(%) |
(%) |
(%) |
total |
small |
large |
3h exposure, without metabolic activation |
|||||||
SC1 |
100 |
72 |
100 |
100 |
100 |
57 |
40 |
SC2 |
|
69 |
|
|
144 |
59 |
78 |
31 |
89 |
85 |
120 |
107 |
66 |
30 |
34 |
63 |
102 |
52 |
74 |
75 |
106 |
49 |
53 |
125 |
90 |
76 |
107 |
96 |
139 |
79 |
53 |
250 |
91 |
94 |
133 |
121 |
90 |
47 |
39 |
500 |
78 |
80 |
113 |
88 |
128 |
56 |
66 |
600 |
68 |
94 |
133 |
90 |
123 |
67 |
49 |
700(1) |
36 |
76 |
107 |
38 |
135 |
80 |
48 |
800(1) |
17 |
84 |
118 |
20 |
121 |
64 |
51 |
MMS |
87 |
51 |
72 |
63 |
933 |
510 |
317 |
3h exposure, with metabolic activation |
|||||||
SC1 |
100 |
81 |
100 |
100 |
104 |
49 |
51 |
SC2 |
|
90 |
|
|
104 |
61 |
38 |
7.8 |
78 |
66 |
77 |
60 |
145 |
76 |
62 |
16 |
79 |
72 |
85 |
67 |
140 |
71 |
62 |
31 |
93 |
59 |
69 |
64 |
153 |
79 |
68 |
63 |
90 |
67 |
78 |
71 |
132 |
66 |
60 |
125 |
111 |
72 |
85 |
94 |
131 |
87 |
38 |
250 |
98 |
78 |
91 |
89 |
118 |
60 |
53 |
500 |
96 |
83 |
96 |
93 |
121 |
67 |
49 |
1000(1) |
76 |
93 |
108 |
82 |
111 |
67 |
38 |
CP |
50 |
32 |
37 |
18 |
2316 |
1167 |
748 |
Note: all calculations were made without rounding off
RSG = Relative Suspension Growth; CE = Cloning Efficiency; RCE = Relative Cloning Efficiency;
RTG = Relative Total Growth; SC = Solvent control = DMSO;
MMS = Methylmethanesulfonate; CP = Cyclophosphamide
(1) = The test item precipitated in the exposure medium
Table 3: Experiment 2: Cytotoxic and mutagenic response of the test substance ester in the mouse lymphoma
l5178Y test system
Dose |
RSG |
CE day2 |
RCE |
RTG |
Mutation frequency per 106survivors |
||
(µg/mL) |
(%) |
(%) |
(%) |
(%) |
total |
small |
large |
24 h exposure, without metabolic activation |
|||||||
SC1 |
100 |
88 |
100 |
100 |
104 |
51 |
48 |
SC2 |
|
91 |
|
|
93 |
44 |
45 |
7.8 |
110 |
94 |
105 |
115 |
85 |
37 |
45 |
16 |
106 |
93 |
104 |
110 |
89 |
46 |
40 |
31 |
113 |
66 |
74 |
84 |
119 |
45 |
69 |
63 |
100 |
77 |
86 |
86 |
149 |
81 |
60 |
125 |
101 |
80 |
90 |
91 |
128 |
80 |
42 |
250 |
93 |
71 |
80 |
74 |
147 |
61 |
79 |
500 |
84 |
81 |
91 |
77 |
116 |
46 |
65 |
700(1) |
65 |
71 |
80 |
52 |
133 |
69 |
58 |
MMS |
97 |
55 |
61 |
59 |
789 |
388 |
317 |
Note: all calculations were made without rounding off
RSG = Relative Suspension Growth; CE = Cloning Efficiency; RCE = Relative Cloning Efficiency;
RTG = Relative Total Growth; SC = Solvent control = DMSO; MMS = Methylmethanesulfonate
(1) = The test item precipitated in the exposure medium
Table 4: Experiment 1: Cell Counts and Subculture Data (With Metabolic Activation)
|
Day 0 |
Day 1 |
Day 2 |
|
|
|
Dose |
total amount of cells before treatment (x 106) |
cell count (x105c/ml) |
subculture x 106 total amount (1) |
cell count (x105c/ml) |
RSG
|
SG |
(µg/mL) |
|
|
|
|
(%) |
|
SC1 |
8 |
4.8 |
4.0 |
7.9 |
100 |
19 |
SC2 |
8 |
4.4 |
4.0 |
8.0 |
|
18 |
7.8 |
8 |
3.7 |
4.0 |
7.7 |
78 |
|
16 |
8 |
3.5 |
4.0 |
8.2 |
79 |
|
31 |
8 |
4.1 |
4.0 |
8.3 |
93 |
|
63 |
8 |
4.1 |
4.0 |
8.0 |
90 |
|
125 |
8 |
5.4 |
4.0 |
7.5 |
111 |
|
250 |
8 |
4.4 |
4.0 |
8.1 |
98 |
|
500 |
8 |
4.7 |
4.0 |
7.5 |
96 |
|
1000(2) |
8 |
3.6 |
4.0 |
7.7 |
76 |
|
CP |
8 |
2.5 |
4.0 |
7.2 |
50 |
|
Note: all calculations were made without rounding off
(1) = cell density 1.25 x 105c/ml
(2) = the test item precipitated in the exposure medium
Table 5: Experiment 1: Selection data and cloning efficiency
Dose (µg/mL) |
Mutant colonies |
Cloning efficiency (at day 2) |
Mutation frequency per 106survivors |
|||||||||||||||||
number of wells with mutants per selection plate(1) |
Total number of mutants |
No. of empty wells per cloning plate |
Total number of empty wells |
CE x 100% |
||||||||||||||||
1 |
2 |
3 |
4 |
5 |
|
|
|
1 |
2 |
|
|
total |
small |
large |
||||||
without metabolic activation |
||||||||||||||||||||
|
s |
1 |
s |
1 |
s |
1 |
s |
1 |
s |
1 |
s |
1 |
s + 1 |
|
|
|
|
|
|
|
SC1 |
3 |
7 |
10 |
6 |
3 |
6 |
11 |
4 |
11 |
4 |
38 |
27 |
65 |
47 |
46 |
93 |
72 |
100 |
57 |
40 |
SC2 |
6 |
6 |
6 |
16 |
9 |
6 |
8 |
10 |
9 |
11 |
38 |
49 |
87 |
47 |
49 |
96 |
69 |
144 |
59 |
78 |
31 |
4 |
3 |
4 |
7 |
7 |
6 |
3 |
5 |
6 |
6 |
24 |
27 |
51 |
43 |
39 |
82 |
85 |
66 |
30 |
34 |
63 |
3 |
6 |
5 |
4 |
6 |
6 |
4 |
5 |
6 |
5 |
24 |
26 |
50 |
63 |
51 |
114 |
52 |
106 |
49 |
53 |
125 |
7 |
6 |
14 |
6 |
13 |
8 |
9 |
11 |
11 |
6 |
54 |
37 |
91 |
54 |
36 |
90 |
76 |
139 |
79 |
53 |
250 |
8 |
5 |
10 |
6 |
10 |
10 |
9 |
5 |
4 |
8 |
41 |
34 |
75 |
41 |
34 |
75 |
94 |
90 |
47 |
39 |
500 |
8 |
13 |
7 |
8 |
7 |
6 |
12 |
7 |
7 |
14 |
41 |
48 |
89 |
41 |
45 |
86 |
80 |
128 |
56 |
66 |
600 |
10 |
6 |
13 |
10 |
11 |
10 |
8 |
9 |
15 |
7 |
57 |
42 |
99 |
36 |
39 |
75 |
94 |
123 |
67 |
49 |
700 (2) |
12 |
9 |
14 |
9 |
7 |
4 |
8 |
6 |
14 |
6 |
55 |
34 |
89 |
42 |
48 |
90 |
76 |
135 |
80 |
48 |
800 (2) |
12 |
8 |
6 |
8 |
7 |
7 |
12 |
9 |
12 |
7 |
49 |
39 |
88 |
45 |
38 |
83 |
84 |
121 |
64 |
51 |
MMS |
22 26 |
12 16
|
31 23 |
12 11 |
26 18 |
15 15 |
22 15 |
17 17 |
19 19 |
16 13 |
221 |
144 |
365 |
56 |
59 |
115 |
51 |
933 |
510 |
317 |
with metabolic activation |
||||||||||||||||||||
|
s |
1 |
s |
1 |
s |
1 |
s |
1 |
s |
1 |
s |
1 |
s + 1 |
|
|
|
|
|
|
|
SC1 |
8 |
8 |
7 |
7 |
7 |
9 |
9 |
7 |
6 |
7 |
37 |
38 |
75 |
42 |
43 |
85 |
81 |
104 |
49 |
51 |
SC2 |
8 |
7 |
10 |
7 |
11 |
5 |
14 |
3 |
7 |
10 |
50 |
32 |
82 |
39 |
39 |
78 |
90 |
104 |
61 |
38 |
7.8 |
10 |
7 |
13 |
5 |
12 |
8 |
7 |
8 |
4 |
10 |
46 |
38 |
84 |
48 |
51 |
99 |
66 |
145 |
76 |
62 |
16 |
9 |
8 |
6 |
8 |
13 |
7 |
11 |
8 |
8 |
10 |
47 |
41 |
88 |
44 |
49 |
93 |
72 |
140 |
71 |
62 |
31 |
7 |
5 |
7 |
13 |
11 |
5 |
5 |
7 |
13 |
7 |
43 |
37 |
80 |
55 |
51 |
106 |
59 |
153 |
79 |
68 |
63 |
8 |
11 |
10 |
10 |
7 |
5 |
7 |
5 |
9 |
6 |
41 |
37 |
78 |
50 |
48 |
98 |
67 |
132 |
66 |
60 |
125 |
22 |
3 |
10 |
6 |
8 |
7 |
8 |
4 |
9 |
6 |
57 |
26 |
83 |
49 |
44 |
93 |
72 |
131 |
87 |
38 |
250 |
6 |
11 |
9 |
4 |
9 |
8 |
13 |
9 |
6 |
6 |
43 |
38 |
81 |
45 |
43 |
88 |
78 |
118 |
60 |
53 |
500 |
11 |
7 |
10 |
8 |
11 |
8 |
12 |
9 |
6 |
5 |
50 |
37 |
87 |
38 |
46 |
84 |
83 |
121 |
67 |
49 |
1000(2) |
10 |
10 |
10 |
7 |
7 |
6 |
15 |
3 |
14 |
7 |
56 |
33 |
89 |
39 |
37 |
76 |
93 |
111 |
67 |
38 |
CP |
33 28 |
16 20 |
35 22 |
16 23 |
26 32 |
28 23 |
28 30 |
18 21 |
26 36 |
21 16 |
296 |
202 |
498 |
76 |
64 |
140 |
32 |
2316 |
1167 |
748 |
s = small colonies
l = large colonies
(1) = Solvent controls and treatment groups five plates with 2000 cells/well and the positive controls ten plates with 1000 cells/well
(2) = The test item precipitated in the exposure medium
MMS, Methylmethanesulfonate
CP, Cyclophosphamide
Table 6: Experiment 2: Cell Counts and Subculture Data (Without Metabolic Activation)
|
24 h Treatment |
Day 1 |
Day 2 |
|
|
|||
Dose |
total amount of cells before treatment (x 106) |
total amount of cells after treatment (x 106) |
subculture x 106 total amount (1) |
cell count (x105c/ml) |
subculture x 106 total amount (1) |
cell count (x105c/ml) |
RSG
|
SG |
(µg/mL) |
|
|
|
|
|
|
(%) |
|
SC1 |
6 |
22.0 |
4.0 |
5.3 |
4.0 |
7.0 |
100 |
87 |
SC2 |
6 |
22.0 |
4.0 |
5.4 |
4.0 |
6.8 |
110 |
86 |
7.8 |
6 |
22.0 |
4.0 |
5.5 |
4.0 |
7.3 |
106 |
|
16 |
6 |
22.4 |
4.0 |
5.8 |
4.0 |
6.6 |
113 |
|
31 |
6 |
24.4 |
4.0 |
5.2 |
4.0 |
7.2 |
100 |
|
63 |
6 |
23.2 |
4.0 |
5.3 |
4.0 |
6.6 |
101 |
|
125 |
6 |
23.4 |
4.0 |
5.1 |
4.0 |
6.8 |
93 |
|
250 |
6 |
21.8 |
4.0 |
5.0 |
4.0 |
6.9 |
84 |
|
500 |
6 |
19.2 |
4.0 |
5.4 |
4.0 |
6.6 |
65 |
|
700(2) |
6 |
14.6 |
4.0 |
5.7 |
4.0 |
6.3 |
97 |
|
Note: all calculations were made without rounding off
(1) = cell density 1.25 x 105c/ml
(2) = the test item precipitated in the exposure medium
Table 7: Experiment 2: Selection data and cloning efficiency
Dose (µg/mL) |
Mutant colonies |
Cloning efficiency (at day 2) |
Mutation frequency per 106survivors |
|||||||||||||||||
number of wells with mutants per selection plate(1) |
Total number of mutants |
No. of empty wells per cloning plate |
Total number of empty wells |
CE x 100% |
||||||||||||||||
1 |
2 |
3 |
4 |
5 |
|
|
|
1 |
2 |
|
|
total |
small |
large |
||||||
without metabolic activation |
||||||||||||||||||||
|
s |
1 |
s |
1 |
s |
1 |
s |
1 |
s |
1 |
s |
1 |
s + 1 |
|
|
|
|
|
|
|
SC1 |
12 |
6 |
10 |
9 |
7 |
12 |
9 |
6 |
3 |
6 |
41 |
39 |
80 |
42 |
38 |
80 |
88 |
104 |
51 |
48 |
SC2 |
5 |
7 |
5 |
11 |
8 |
9 |
9 |
7 |
10 |
4 |
37 |
38 |
75 |
39 |
38 |
77 |
91 |
93 |
44 |
45 |
7.8 |
11 |
8 |
8 |
6 |
8 |
10 |
3 |
6 |
2 |
9 |
32 |
39 |
71 |
39 |
36 |
75 |
94 |
85 |
37 |
45 |
16 |
9 |
6 |
5 |
7 |
9 |
9 |
10 |
4 |
6 |
8 |
39 |
34 |
73 |
35 |
41 |
76 |
93 |
89 |
46 |
40 |
31 |
5 |
8 |
3 |
9 |
8 |
8 |
5 |
10 |
7 |
7 |
28 |
42 |
70 |
49 |
50 |
99 |
66 |
119 |
45 |
69 |
63 |
9 |
5 |
7 |
16 |
15 |
9 |
14 |
9 |
11 |
3 |
56 |
42 |
98 |
50 |
39 |
89 |
77 |
149 |
81 |
60 |
125 |
17 |
7 |
14 |
10 |
9 |
3 |
8 |
4 |
10 |
7 |
58 |
31 |
89 |
37 |
49 |
86 |
80 |
128 |
80 |
42 |
250 |
9 |
9 |
8 |
16 |
6 |
10 |
8 |
11 |
9 |
5 |
40 |
51 |
91 |
46 |
48 |
94 |
71 |
147 |
61 |
79 |
500 |
8 |
8 |
8 |
11 |
9 |
6 |
3 |
11 |
7 |
12 |
35 |
48 |
83 |
48 |
37 |
85 |
81 |
116 |
46 |
65 |
700(2) |
7 |
8 |
12 |
7 |
6 |
9 |
8 |
10 |
12 |
4 |
45 |
38 |
83 |
45 |
49 |
94 |
71 |
133 |
69 |
58 |
MMS |
10 21 |
20 11 |
17 14 |
16 23 |
23 17 15
|
15 13 |
23 15
|
15 15 |
25 19 |
12 13 |
184 |
153 |
337 |
53 |
58 |
111 |
55 |
789 |
388 |
317 |
s = small colonies
l = large colonies
(1)= Solvent controls and treatment groups five plates with 2000 cells/well and the positive controls ten plates with 1000 cells/well
(2)= The test item precipitated in the exposure medium
MMS, Methylmethanesulfonate
CP, Cyclophosphamide
Table 8: Historical control data of the spontaneous mutation frequencies of the vehicle controls for the mouse lymphoma assay
|
Mutation frequency per 106 survivors |
||
|
- S9-mix |
+ S9-mix |
|
|
3 hour treatment |
24 hour treatment |
3 hour treatment |
Mean |
101 |
98 |
100 |
SD |
30 |
31 |
30 |
n |
279 |
262 |
293 |
Upper control limit (95% control limits) |
170 |
162 |
165 |
Lower control limit (95% control limits) |
31 |
34 |
36 |
SD = Standard deviation
n = Number of observations
Distribution historical negative control data from experiments performed between
September 2015 and September 2018.
Table 9: Historical control data of the spontaneous mutation frequencies of the positive controls for the mouse lymphoma assay
|
Mutation frequency per 106 survivors |
||
|
- S9-mix |
+ S9-mix |
|
|
3 hour treatment |
24 hour treatment |
3 hour treatment |
Mean |
803 |
695 |
1545 |
SD |
253 |
223 |
887 |
n |
142 |
132 |
151 |
Upper control limit (95% control limits) |
1533 |
1270 |
3954 |
Lower control limit (95% control limits) |
72 |
119 |
-864 |
SD = Standard deviation
n = Number of observations
Distribution historical positive control data from experiments performed between September
2015 and September 2018.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Several genotoxicity tests were conducted with the registration substance to evaluate its genotoxic potential. In detail, the following studies have been performed with the test substance:
- Genetic toxicity in bacteria (Ames)
A bacterial gene mutation assay (Ames test) with Bis(2-(2-butoxyethoxy)ethyl) adipate was performed according to OECD Guideline 471 and in compliance with GLP (The American Chemistry Council, 2011). Two independent experiments were performed (plate incorporation and pre-incubation), both in the presence or absence of metabolic activation (S9 mix), in the S. typhimurium strains TA 1535, TA 1537, TA 98 and TA 100 and E. coli WP2 uvr A pKM 101 with test substance concentrations ranging from 0.15 to 5000 µg/plate for an exposure period of 48 h. No cytotoxicity was observed in any of the tester strains up to the limit concentration of 5000 µg/plate. No increase in mean revertant number was observed in any bacterial strain after exposure to the test substance at any test concentration in both experiments. The solvent and positive controls showed the expected results and thus confirmed the efficiency of the assay. Under the conditions of this assay, the test substance did not induce mutagenicity in the selected strains of S. typhimurium (TA 1535, TA 1537, TA 98 and TA 100) and E. coli WP2 uvr A pKM 101 in the absence and presence of metabolic activation, respectively. (was already in the dossier)
- Cytogenicity/micronucleus test in human peripheral lymphocytes
A GLP conformed micronucleus test was performed according to OECD guideline 487 (Emery Oleochemicals, 2019). The potential of the registration substance to induce micronuclei in cultured peripheral human lymphocytes was investigated, either in the presence or absence of a metabolic activation system (S9-mix).
A dose-range-finding test was performed to choice the appropriate doses for the main study. The following concentrations and conditions were investigated:
31.3, 62.5, 125, 250, 500 and 1000 μg/mL (+/- S9, 3h exposure) and 62.5, 125, 250, 500, 1000 and 2000 μg/mL (- S9, 24h exposure). Precipitation was observed at dose levels of 125 μg/ml and upwards after adding the test substance to the culture medium. However, the amount of precipitate decreased during incubation. After 3 h the precipitate was only observed at dose levels of 1000 μg/mL and upwards. Substantial toxicity determined by CBPI (at least 55 ± 5 % cytostasis) were observed at 1000 µg/mL (3h exposure and 24 h exposure -S9) and 2000 µg/mL (24 h exposure -S9). Doses selected for the main experiments were based on precipitation.
The possible clastogenicity and aneugenicity of the test substance was tested in two independent experiments.In the first cytogenetic assay lymphocytes were cultured for 46 ± 2 h and thereafter exposed to the test substance at50, 500, 750 and 1000 μg/mL,dissolved in dimethylsulfoxid,for 3 h in the absence and presence of S9-mix. After 3 h exposure, the cells were separated from the exposure medium and were re-suspended in 5 mL culture medium with cytochalasin B (5 μg/mL) and incubated for another 24 h. In the second cytogenetic assay lymphocytes were exposed for an extended exposure time of 24 h. Lymphocytes were cultured for 46 ± 2 h and thereafter exposed in duplicate to the test substance at50, 500, 750 and 1000 μg/mLwith cytochalasin B (5 μg/mL) for 24 h in the absence of S9-mix.
In both experiments, dimethylsulfoxid (1.0% (v/v) in the final culture medium) served as vehicle control. Mitomycin C (0.25 and 0.38 μg/mL) was used as positive control for a direct acting clastogen and colchicine (0.1 μg/mL) was used as positive control for a direct acting aneugen during the 3 and 24 h exposure period. Cyclophosphamide (15 and 17.5 μg/mL) was used as an indirect acting clastogen, requiring metabolic activation, during the 3 h exposure period.
In the first cytogenetic experiments, thepositive control did not give a proper response in the presence of S9-mix and was thus rejected. The first experiment (1A) was therefore repeated. Since precipitates were observed at 750 and 1000 mg/mL in the first experiment, the following concentrations were used in the repeat experiment (1A) 50, 500 and 750 μg/mL.
In both, the first (1A) and the second cytogenicity experiment, the test substance did not induce a statistically significant or biologically relevant increase in the number of mono- and binucleated cells with micronuclei in the absence and presence of S9-mix.
In the first cytogenetic assay, 1 A, precipitate was observed at the highest dose level (750 μg/ml). Substantial toxicity (at least 55 ± 5 % cytostasis) was not determined at any test concentration.
In the second cytogenetic assay, precipitate was observed at the two highest dose levels (750 and 1000 μg/ml). In addition, substantial toxicity was reached at 750 μg/ml. Therefore concentrations of 50, 500 and 750 μg/ml were selected for scoring of micronuclei.
Vehicle and positive controls proofed the validity of the study. The number of mono- and binucleated cells with micronuclei found in the vehicle control was within the 95% control limits of the distribution of the historical negative control database. The positive control chemicals, mitomycin C and cyclophosphamide both produced a statistically significant increase in the number of binucleated cells with micronuclei. Colchicine produced a statistically significant increase in the number of mononucleated cells with micronuclei. In addition, the number of mono- and binucleated cells with micronuclei found in the positive control cultures was within the 95% control limits of the distribution of the historical positive control database. It was therefore concluded that the test conditions were adequate and that the metabolic activation system (S9-mix) functioned properly.
In conclusion, the test substance was not clastogenic or aneugenic in human lymphocytes under the experimental conditions.
- Gene mutation in mammalian cells
A GLP guideline study on gene mutation in mammalian cells was performed according to OECD Guideline 490 (Emery Oleochemicals, 2019). In this study the ability of the test material to induce forward mutations at the thymidine kinase (TK) locus was investigated in L5178Y mouse lymphoma cells, either in the absence (3h or 24 h exposure period) or presence (3h exposure period) of a metabolic system (S9-mix), prepared from male rats treated with phenobarbital (80 mg/kg body weight) and ß-naphthoflavone (100 mg/kg body weight).
Preliminary testing of test substance solubility in dimethyl sulfoxide revealed precipitates in the exposure medium at concentrations of 1000 μg/mL and above. Therefore, 1000 µg/mL was used as the highest test substance concentration in the dose range-finding test.
In this dose-range finding test, lymphoma cells were treated with the test item, dissolved in dimethyl sulfoxide at 63, 125, 250, 500 and 1000 μg/mL (3 h, +/- S9 and 24 h, -S9). Both for the dose range finding experiment and the main tests, dimethyl sulfoxide at a concentration of 1% (v/v) served as negative control. Cyclophosphamide, dissolved dissolved in Hanks’ balanced salt solution (HBSS) without calcium and magnesium, was used as positive control for an indirect acting mutagen, requiring metabolic activation at an concentration of 7.5 μg/mL (3 h exposure period). Methyl methanesulfonate, dissolved dimethyl sulfoxid, was used as a direct acting mutagen at concentrations of 15 and 5 μg/mL (3 and 24 h exposure periods, respectively).
Precipitates were observed at the highest test substance concentration at all treatment conditions. Cytotoxicity, determined by relative suspension growth was 74% at 500 μg/mL and 0% at 1000 µg/mL compared to the relative suspension growth of the solvent control in the absence of metabolic activation (3h exposure). With metabolic activation, no toxicity determined as relative suspension growth was observed up to the highest test substance concentration of 1000 μg/mL compared to the vehicle control (3h exposure). The relative suspension growth was 37% at an test substance concentration of 1000 μg/mL compared to the relative suspension growth of the vehicle control without metabolic activation. (24h exposure).
Based on precipitation and cytotoxicity in the dose-range finding test the following concentrations were used in the first mutagenicity test (3 h exposure): 16, 31, 63, 125, 250, 500, 600, 700, 800, 900 and 1000 μg/mL (- S9) and 7.8, 16, 31, 63,125, 250, 500 and 1000 μg/mL (+ S9). The second mutagenicity test (24 h exposure) was conducted with the following test substance concentrations: 7.8, 16, 31, 63, 125, 250, 500 and 700 μg/mL (- S9).
In the first experiment, the test item precipitated in the culture medium at dose levels of 700 μg/mL and above.
Relative total growth (RTG) was reduced to 20% in the absence of S9-mix at a dose of 800 µg/ml and above and doses between 31 and 800 µg/mL were selected for evaluation. No substantial toxicity was observed in the presence of S9-mix, thus all dose levels were evaluated. Both in the presence and absence of S9-mix, no biologically relevant increase in the mutation frequency at the TK locus was observed after treatment with the test substance. The numbers of small and large colonies were comparable to the numbers of small and large colonies of the vehicle controls.
In the second experiment, no severe toxicity was observed up to and including the highest tested dose level and all dose levels were evaluated. Precipitates occurred at the highest dose level tested. Also after a longer exposure period, no biologically relevant increase in the mutation frequency at the TK locus was observed after treatment with the test substance without metabolic activation. The numbers of small and large colonies in the test item treated cultures were comparable to the numbers of small and large colonies of the solvent controls.
Vehicle and positive controls proved the validity of the study. The mutation frequency of the vehicle control was within the acceptability criteria of this assay and within the 95% control limits of the distribution of the historical negative control database. The positive control substances, methyl methanesulfonate and cyclophosphamide, both produced significant increases in the mutation frequency. In addition, the mutation frequencies of the positive controls were within the 95% control limits of the distribution of the historical positive control database.
In conclusion, both in the first (3h exposure) and second (24 h exposure) mutation test the test substance did not induce a biologically relevant increase in the mutation frequency in the absence and presence of metabolic activation. Therefore, the test substance was not mutagenic in the mouse lymphoma L5178Y test system under the described conditions.
Conclusion on genetic toxicity
Overall, the available in vitro studies on genetic toxicity do not indicate that the test substance exhibits genotoxic properties. The test substance did not induce gene mutations in bacteria or mammalian cells and did not induce micronuclei in peripheral human lymphocytes.
Justification for classification or non-classification
The available genotoxicity data obtained for the test substance are conclusive but not sufficient for classification according to Regulation (EC) No. 1272/2008 (CLP).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.